Prilenia cares deeply about patients and their families impacted by neurodegenerative diseases. We recognize the emotional and social impact a neurodegenerative disease can have on a patient, their families, and caregivers.
We are dedicated to use our science to bring hope by developing treatments that may slow progression and maintain quality of life. We deeply value the inspiration and purpose we get from patient stories that we hear every day.
Pridopidine is an oral drug currently in development for the treatment of Huntington’s disease and ALS. It is administered in a small easy-to-swallow capsule twice a day.
Multiple clinical studies have been conducted providing important understanding about pridopidine’s safety, mechanism of action, and efficacy.
Recent imaging studies in humans show that pridopidine enters the brain and spinal cord, where it activates a protein called the sigma-1 receptor (S1R).
The S1R is highly expressed in the brain where it regulates several cellular mechanisms common to neurodegenerative diseases such as HD and ALS.
Activation of the S1R by pridopidine enhances the clearance of toxic proteins, enhances energy production, and reduces cellular stress and inflammation. These mechanisms are crucial for a neuron’s function and survival.
Studies in animal models and human cells show that pridopidine prevents neuronal cell death, and strengthens and enhances the connections between neurons.